Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Issued: 2013-2025

Historic Shares Issued for Ocular Therapeutix (OCUL) over the last 9 years, with Jun 2025 value amounting to $89.8 million.

  • Ocular Therapeutix's Shares Issued was N/A to $89.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $518.1 million, marking a year-over-year change of. This contributed to the annual value of $316.4 million for FY2024, which is 169.79% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Shares Issued of $89.8 million as of Q2 2025, which was up 2,047.79% from $4.2 million recorded in Q1 2025.
  • Ocular Therapeutix's Shares Issued's 5-year high stood at $316.4 million during Q1 2024, with a 5-year trough of $32,000 in Q3 2022.
  • Its 3-year average for Shares Issued is $75.4 million, with a median of $8.7 million in 2023.
  • As far as peak fluctuations go, Ocular Therapeutix's Shares Issued plummeted by 99.89% in 2021, and later soared by 405,480.77% in 2024.
  • Ocular Therapeutix's Shares Issued (Quarterly) stood at $172,000 in 2021, then skyrocketed by 147.67% to $426,000 in 2022, then surged by 25,188.50% to $107.7 million in 2023, then skyrocketed by 405,480.77% to $316.4 million in 2024, then crashed by 98.68% to $89.8 million in 2025.
  • Its Shares Issued was $89.8 million in Q2 2025, compared to $4.2 million in Q1 2025 and $316.4 million in Q1 2024.